ArrowMark Colorado Holdings’s Black Diamond Therapeutics BDTX Stock Holding History

ArrowMark Colorado Holdings’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-70,000	Closed	-$1.7M	–	344
2021 Q1	$1.7M	Hold	70,000	–	–	0.01%	283
2020 Q4	$2.24M	Hold	70,000	–	–	0.02%	260
2020 Q3	$2.12M	Hold	70,000	–	–	0.02%	255
2020 Q2	$2.95M	Hold	70,000	–	–	0.03%	213
2020 Q1	$1.75M	Buy	+70,000	New	+$2.13M	0.02%	222

Other funds holding BDTX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ArrowMark Colorado Holdings's BDTX Position: Q2 2021 in Review

ArrowMark Colorado Holdings sold out of Black Diamond Therapeutics (BDTX) in Q2 2021, closing a stake of 70,000 shares — an estimated $1.7M sold.

ArrowMark Colorado Holdings first reported a position in BDTX in Q1 2020 and held it in 5 quarters. The position peaked at $2.95M in Q2 2020. 102 funds tracked by Wall St. Rank hold BDTX as of Q2 2021.

ArrowMark Colorado Holdings reported no remaining Black Diamond Therapeutics position as of Q2 2021 after selling out during the quarter.
ArrowMark Colorado Holdings sold 70,000 Black Diamond Therapeutics shares in Q2 2021, an estimated $1.7M.
ArrowMark Colorado Holdings first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 5 quarters.
ArrowMark Colorado Holdings's Black Diamond Therapeutics position peaked at $2.95M in Q2 2020.
102 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2021.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2021, filed 16 Aug 2021.